Bizaxofusp - Medicenna Therapeutics
Alternative Names: cpIL4-PE; Empowered Superkine targeting the IL-4R - Medicenna Therapeutics; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321Latest Information Update: 02 Dec 2024
At a glance
- Originator National Institutes of Health (USA); Neurocrine Biosciences
- Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
- Class Antineoplastics; Immunotoxins; Interleukins; Recombinant fusion proteins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Brain metastases; Glioblastoma
- No development reported Bladder cancer; Brain cancer; Diffuse intrinsic pontine glioma
- Discontinued Solid tumours
Most Recent Events
- 25 Nov 2024 Medicenna obtains agreement from the U.S. FDA on the study design for the registrational phase III LIGHT™ trial for Glioblastamo
- 25 Nov 2024 Pharmacodynamics data from a preclinical trials in Glioblastoma released by Medicenna Therapeutics
- 03 Jun 2024 Updated efficacy data from a phase IIb trial in Glioblastoma released by Medicenna Therapeutics